Almirall, S.A.
Clinical trials sponsored by Almirall, S.A., explained in plain language.
Almirall, S.A.
ALM
BME
A pharmaceutical company focused on dermatology and medical aesthetics.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for painful skin condition: experimental drug LAD328 enters phase 2 trial Results expected Feb 2027 (estimated)
- Eczema drug trial could mean fewer shots for patients Results expected Apr 2027 (estimated)
- New hope for HS sufferers: LAD191 enters Mid-Stage trial Results expected May 2027 (estimated)
- New drug LAD106 enters first human safety tests Results expected May 2027 (estimated)
- New drug could help regrow hair in severe alopecia Results expected Jun 2027 (estimated)